Keros Therapeutics, Inc. Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements
Keros Therapeutics, Inc. (KROS) reported Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements of 0 shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Notes
us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements · last filed 2026-08-03
- Keros Therapeutics, Inc. incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2026-06-30 was 0.00 shares.
- Keros Therapeutics, Inc. incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2026-03-31 was 0.00 shares, a 100.00% decline year-over-year.
- Keros Therapeutics, Inc. incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2025-09-30 was 0.00 shares.
- Keros Therapeutics, Inc. incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2025-06-30 was 0.00 shares.
- Keros Therapeutics, Inc. incremental common shares attributable to dilutive effect of share-based payment arrangements for fiscal 2025 was 637.89K shares.
- Keros Therapeutics, Inc. incremental common shares attributable to dilutive effect of share-based payment arrangements for fiscal 2024 was 0.00 shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 3 month | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 6 month | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 9 month | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 12 month |
|---|---|---|---|---|
| 2026-06-30 | 0.00 shares 10-Q · filed 2026-08-03 | 0.00 shares 10-Q · filed 2026-08-03 | ||
| 2026-03-31 | 0.00 shares 10-Q · filed 2026-05-14 | |||
| 2025-12-31 | 637.89K shares 10-K · filed 2026-03-04 | |||
| 2025-09-30 | 0.00 shares 10-Q · filed 2025-11-05 | 603.59K shares 10-Q · filed 2025-11-05 | ||
| 2025-06-30 | 0.00 shares 10-Q · filed 2026-08-03 | 567.48K shares 10-Q · filed 2026-08-03 | ||
| 2025-03-31 | 461.97K shares 10-Q · filed 2026-05-14 | |||
| 2024-12-31 | 0.00 shares 10-K · filed 2026-03-04 | |||
| 2024-09-30 | 0.00 shares 10-Q · filed 2025-11-05 | 0.00 shares 10-Q · filed 2025-11-05 | ||
| 2024-06-30 | 0.00 shares 10-Q · filed 2025-08-06 | 0.00 shares 10-Q · filed 2025-08-06 | ||
| 2024-03-31 | 0.00 shares 10-Q · filed 2025-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |